|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2000; 36:668-673 © 2000 by the American College of Cardiology Foundation |
a Division of Cardiology, The Johns Hopkins Hospital, Baltimore, Maryland, USA
b Department of Medicine, Cleveland Clinic Florida, Fort Lauderdale, Florida, USA
Manuscript received December 8, 1999; revised manuscript received March 7, 2000, accepted April 14, 2000.
Reprint requests and correspondence to: Dr. Roger S. Blumenthal, Preventive Cardiology, Johns Hopkins Hospital, 600 North Wolfe Street, Carnegie 538, Baltimore, Maryland 21287
rblument{at}jhmi.edu
The recent publication of the Atorvastatin Versus Revascularization Treatment (AVERT) trial has renewed debate on the optimal management strategy for relatively stable patients with coronary artery disease. Currently, coronary angiography and percutaneous coronary intervention are often performed in stable patients with good exercise tolerance who have not been treated with proven medications such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comprehensive lifestyle modification. We review the results of prior trials comparing medical therapy with angioplasty and assess their strengths and limitations and then make conclusions about the aggregate data. Next, we describe the ongoing Clinical Outcome Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which will be the largest of the studies comparing optimal medical therapy and percutaneous revascularization. This study will employ intensive medical management in all patients with coronary disease, and the incremental benefit of state of the art revascularization techniques in terms of clinical event reduction, quality of life issues and cost-effectiveness will be addressed. For now, aggressive medical therapy and revascularization should be viewed as complementary rather than opposing strategies. All patients with coronary heart disease should receive proven medical and lifestyle prescriptions to favorably alter the atherosclerotic process. Percutaneous revascularization without comprehensive risk factor modification is a suboptimal therapeutic strategy.
| ||||||||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  J. G Regensteiner, W. R Hiatt, J. R Coll, M. H Criqui, D. Treat-Jacobson, M. M McDermott, and A. T Hirsch The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program Vascular Medicine, February 1, 2008; 13(1): 15 - 24. [Abstract] [PDF]
|
|
|
|
 |
|
 D. T. Nash The Case for Medical Treatment in Chronic Stable Coronary Artery Disease Arch Intern Med, December 12, 2005; 165(22): 2587 - 2589. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.T. Ong The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient QJM, August 1, 2005; 98(8): 599 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Bonetti, C. Kaiser, M. J. Zellweger, L. Grize, P. Erne, R. A. Schoenenberger, M. E. Pfisterer, and TIME Investigators Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 29 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Curtis and H. M. Krumholz Keeping the Patient in View: Defining the Appropriateness of Percutaneous Coronary Interventions Circulation, December 21, 2004; 110(25): 3746 - 3748. [Full Text] [PDF]
|
|
|
|
 |
|
 W S Weintraub, E M Mahoney, Z Zhang, H Chu, J Hutton, M Buxton, J Booth, F Nugara, R H Stables, P Dooley, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial Heart, July 1, 2004; 90(7): 782 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Blumenthal and T. J. Gluckman New insights into the relationship between myocardial perfusion and lipid-lowering J. Am. Coll. Cardiol., August 20, 2003; 42(4): 611 - 613. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pfisterer, P. Buser, S. Osswald, U. Allemann, W. Amann, W. Angehrn, E. Eeckhout, P. Erne, W. Estlinbaum, G. Kuster, et al. Outcome of Elderly Patients With Chronic Symptomatic Coronary Artery Disease With an Invasive vs Optimized Medical Treatment Strategy: One-Year Results of the Randomized TIME Trial JAMA, March 5, 2003; 289(9): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Futterman and L. Lemberg Seminal Changes in the Management of the Acute Coronary Event: Current Concepts Am. J. Crit. Care., January 1, 2003; 12(1): 73 - 76. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Klein Treatment patterns in stable angina: objectives and reality Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O8 - O11. [Abstract] [PDF]
|
|
|
|
 |
|
 J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal Lipid Disorders : Justification of Methods and Goals of Treatment Chest, September 1, 2001; 120(3): 979 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R Bates Review: percutaneous coronary angioplasty is associated with less angina but more coronary artery bypass grafting in patients with non-acute coronary artery disease than is medical treatment Evid. Based Med., January 1, 2001; 6(1): 13 - 13. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
